Futura Medical PLC’s (LON:FUM) CEO James Barder tells Proactive’s Andrew Scott negotiations over a deal with a partner that would help commercialise their breakthrough erectile dysfunction treatment are at an advanced stage.
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate or carry significant side-effects.
The update came a day after Futura announced interim data which indicated its lead drug can be administered in at least two higher-strength doses.
This has a knock-on positive impact for the imminent phase III clinical trial of MED2002, which is hoped will rubber stamp its huge potential.
